Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer
Executive Summary
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
You may also be interested in...
COX-2 Advisory Committee May Decide Fate of Pfizer’s Bextra
The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class
DTC Ads Should Be Better, Not Banned, In Wake Of Vioxx, Ex-FDAer Pitts Says
The response to the Vioxx withdrawal offers further evidence of the need for FDA and manufacturers to modify the "brief summary" requirement in direct-to-consumer ads, former Associate Commissioner for External Relations Peter Pitts said during a Nov. 10 Drug & Device Dialogue audio conference sponsored by F-D-C Reports and Polidais LLC
COX-2 Advisory Committee May Decide Fate of Pfizer’s Bextra
The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class